SequelSEC

Aura Biosciences, Inc. AURA

Biological Products, (No Diagnostic Substances) · CIK 0001501796 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$112.79M
Fiscal year ended 2025-12-31
Free cash flow
-$85.19M
Fiscal year ended 2025-12-31

Aura Biosciences, Inc. (AURA) reported net income of -$106.19M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Aura Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Aura Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$112.79M-$96.12M-$84.99M-$60.30M-$35.25M-$22.21M
Net income-$106.19M-$86.92M-$76.41M-$58.76M-$35.25M-$22.21M
Research & development$90.30M$73.30M$65.23M$42.24M$25.16M$18.04M
Weighted-average diluted sharesshares 60.34Mshares 49.65Mshares 39.62Mshares 29.94Mshares 5.16MUnavailable
Pretax income-$106.08M-$86.81M-$76.27M-$58.76MUnavailableUnavailable
Income tax expense$108.00K$112.00K$137.00K$0$0$0
Diluted EPS$-1.76$-1.75$-1.93$-1.96$-8.95Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$22.49M$22.81M$19.76M$18.06M$10.09M$4.16M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aura Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$59.52M$31.69M$41.06M$121.58M$149.06M$17.39M
Total assets$169.43M$182.50M$255.08M$223.94M$160.03M$22.10M
Current assets$149.74M$160.62M$231.79M$196.70M$153.70M$18.46M
Total liabilities$32.52M$30.53M$29.23M$28.35M$7.72M$2.74M
Current liabilities$18.38M$14.91M$12.36M$10.46M$7.36M$2.66M
Total equity incl. NCI$136.91M$151.97M$225.85M$195.58M$152.32M-$108.71M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$128.08M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.55M$2.30M$1.79M$2.92M$2.40M$611.00K

Cash flow

Aura Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$84.74M-$79.80M-$63.85M-$54.60M-$32.41M-$24.32M
Capital expenditures$447.00K$1.25M$709.00K$1.09M$2.12M$771.00K
Investing cash flow$35.60M$68.82M-$113.96M-$67.87M-$2.12M-$771.00K
Financing cash flow$77.16M$1.60M$97.29M$95.63M$166.26M$10.04M
Net change in cashUnavailable-$9.39M-$80.52M-$26.84M$131.72M-$15.06M
Stock-based compensation$14.32M$11.72M$8.77M$6.41M$2.31M$736.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Aura Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$85.19M-$81.06M-$64.56M-$55.70M-$34.54M-$25.09M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio8.15x10.77x18.76x18.81x20.90x6.94x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AURA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.